Simultaneous application of a chemotherapeutic agent and a BH3 mimetic can potentially overcome drug resistance in cancers overexpressing anti-apoptotic Bcl-2 proteins and thus increase the treatment success rate. This evidence concerns the gene BCL2 and cancer.